Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.

Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.

It is unknown whether HIV-positive patients experiencing virologic failure (VF) on boosted-PI (PI/r) regimens without drug resistant mutations (DRM) by standard genotyping harbor low-level PI resistant variants. CASTLE compared the efficacy of atazanavir/ritonavir (ATV/r) with lopinavir/ritonavir (L...

Full description

Bibliographic Details
Main Authors: Max Lataillade, Jennifer Chiarella, Rong Yang, Michelle DeGrosky, Jonathan Uy, Daniel Seekins, Birgitte Simen, Elizabeth St John, Elizabeth Moreno, Michael Kozal
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3280244?pdf=render

Internet

http://europepmc.org/articles/PMC3280244?pdf=render

Similar Items